The estimated Net Worth of James Paul Lang is at least $540 Thousand dollars as of 5 June 2024. Mr. Lang owns over 10,061 units of OptimizeRx Corp stock worth over $398,638 and over the last 8 years he sold OPRX stock worth over $0. In addition, he makes $141,848 as Independent Director at OptimizeRx Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Lang OPRX stock SEC Form 4 insiders trading
James has made over 6 trades of the OptimizeRx Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,061 units of OPRX stock worth $73,244 on 5 June 2024.
The largest trade he's ever made was exercising 10,061 units of OptimizeRx Corp stock on 5 June 2024 worth over $73,244. On average, James trades about 713 units every 21 days since 2016. As of 5 June 2024 he still owns at least 54,758 units of OptimizeRx Corp stock.
You can see the complete history of Mr. Lang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Lang biography
James Lang serves as Independent Director of the Company. He brings us more than 25 years of experience in healthcare data, analytic, and technology enabled business services. Mr. Lang is the CEO of Eversana, a leading independent provider of global commercial services to the life science industry, and also presently serves as an executive advisor to Water Street, a strategic private equity firm focused exclusively on building market-leading companies in healthcare. In that capacity, he currently serves as Board Chairman to The Access Group, Health Strategies Group, Alliance Life Sciences, and Dohmen Life Science Services. He is also a director of BioVie, a development-stage company pioneering an innovative therapeutic that targets complications due to liver cirrhosis. Mr. Lang previously served as CEO of Decision Resources Group, a leading healthcare research and consulting company providing high-value healthcare industry analysis and insights, where he helped transform the company into an industry leader. Earlier, he was president of Strategic Decisions Group, a premier global strategy consultancy, and he expanded the life sciences practice and later sold it to IMS Health. He is an active private investor and advisor with healthcare companies, including Boston Heart Diagnostics (acquired by Eurofins) and AlphalmpactRx (acquired by IMS Health). Aside from that provided above, Mr. Lang does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.
What is the salary of James Lang?
As the Independent Director of OptimizeRx Corp, the total compensation of James Lang at OptimizeRx Corp is $141,848. There are 9 executives at OptimizeRx Corp getting paid more, with Stephen Silvestro having the highest compensation of $1,210,200.
How old is James Lang?
James Lang is 55, he's been the Independent Director of OptimizeRx Corp since 2017. There are 9 older and 4 younger executives at OptimizeRx Corp. The oldest executive at OptimizeRx Corp is Gus Halas, 69, who is the Chairman of the Board.
What's James Lang's mailing address?
James's mailing address filed with the SEC is C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM, MA, 02453.
Insiders trading at OptimizeRx Corp
Over the last 2001 years, insiders at OptimizeRx Corp have traded over $20,012,815 worth of OptimizeRx Corp stock and bought 258,753 units worth $1,128,145 . The most active insiders traders include Investment Company, Inc. Awm, Bradley Louis Radoff, and David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of $183,485. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth $73,244.
What does OptimizeRx Corp do?
optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.
What does OptimizeRx Corp's logo look like?
Complete history of Mr. Lang stock trades at OptimizeRx Corp and BioVie
OptimizeRx Corp executives and stock owners
OptimizeRx Corp executives and other stock owners filed with the SEC include:
-
Stephen Silvestro,
Chief Commercial Officer -
William Febbo,
Chief Executive Officer, Director -
William J. Febbo,
CEO & Director -
Stephen L. Silvestro,
Chief Commercial Officer -
Miriam Paramore,
President -
Douglas Baker,
Chief Financial Officer -
Gus Halas,
Chairman of the Board -
Lynn Vos,
Independent Director -
Patrick Spangler,
Independent Director -
James Lang,
Independent Director -
Angelo Campano,
Senior Vice President - Principal of Agency Channels -
Ron Both,
Investor Relations -
Gregory Wasson,
Director -
Todd Inman,
Chief Technology Officer -
Maira Alejandra,
Media Relations Mang. -
Todd Inman,
Chief Technology Officer -
Andrew Jacob D'Silva,
Sr. VP of Corp. Fin. -
Douglas P. Baker,
Exec. VP of Fin. & Accounting -
Edward Stelmakh C.M.A., M.B.A., MBA,
CFO & COO -
Rebecca Whitney,
Sr. VP of Commercial Operations -
Terence J. Hamilton,
Sr. VP of Pharma -
Sheryl Kearney,
HR Mang. -
Marion K Odence-Ford,
Gen. Counsel & Chief Compliance Officer -
Cathy Klema,
Director -
Ellen O'connor Vos,
Director -
Plc Wpp Luxembourg Gamma Th...,
-
Investment Company, Inc. Awm,
10% owner -
Bradley Louis Radoff,
10% owner -
Jack T Pinney,
Director -
Richard Kraniak,
10% owner -
David Lester,
Chairman of the Board -
David Harrell,
Chief Executive Officer -
Terrence Hamilton,
Vice President -
James M Brooks,
SVP of Business Development -
Brian J Dillon,
SR. VP OF PRODUCT & STRATEGY -
Brian Clark Mc Carthy,
Chief Revenue Officer -
Marion Odence Ford,
General Counsel and CCO -
Edward Stelmakh,
CFO/COO -
Doug Besch,
Chief Product Officer -
Theresa Greco,
Chief Commercial Officer